Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk

H. Haller

SUMMARY
The increasing prevalence of hypertension, owing to modern lifestyles and the increasing elderly population, is contributing to the global burden of cardiovascular (CV) disease. Although effective antihypertensive therapies are available, blood pressure (BP) is generally poorly controlled. In addition, the full benefits of antihypertensive therapy can only be realised when target BP is achieved. International guidelines and clinical trial evidence support the use of combination therapy to manage hypertension. In high-risk patients, such as those with coronary artery disease, diabetes and renal dysfunction, BP targets are lower and there is a need for intensive management with combination therapy to control BP and provide additional CV risk reduction benefits. Combinations of antihypertensive agents with different but complementary modes of action improve BP control and may also provide vascular-protective effects. Calcium channel blockers (CCBs) have been shown to be effective in combination with a range of antihypertensive drugs and in different patient populations. As part of a first-line combination strategy, CCBs can provide CV benefits beyond BP control, even in patients at increased CV risk. Benefits include protection against end-organ damage and serious CV events. Indeed, in major intervention trials, these benefits have already been clearly demonstrated. Ongoing studies will provide further data to support the clinical benefits of combination therapy as a first-line treatment approach. Implementation of this approach in clinical practice, together with adherence to global hypertension management guidelines will help ensure patients achieve and sustain BP targets, and reduce the risk of CV events.

Introduction
Hypertension is one of the most important modifiable causes of premature death worldwide, and is estimated to cause 7.1 million premature deaths. Approximately one billion people worldwide have hypertension and the prevalence is predicted to increase dramatically in the next few years (1,2).

Hypertension is a major risk factor for both cardiovascular (CV) and cerebrovascular morbidity and mortality (1), contributing to approximately 50% of all CV events (3). The relationship between blood pressure (BP) and CV risk is continuous – for every 20 mmHg increase in systolic blood pressure (SBP) or 10 mmHg increase in diastolic blood pressure (DBP), the risk of cardiovascular disease (CVD) doubles (4).

Patients with hypertension are also more likely to have associated CV risk factors (5); for example, approximately 50% of patients with hypertension have hypercholesterolaemia and 20–40% have hyperglycaemia. The presence of multiple risk factors increases the risk of CV events associated with hypertension. The most common risk factors for CVD include advanced age (> 55 years for men and > 65 years for women), smoking, dyslipidaemia, family history of premature CVD, abdominal obesity, abnormal C-reactive protein levels and clinical conditions such as diabetes and renal disease (6). As a result, current treatment guidelines emphasise the importance of risk stratification to determine BP targets and appropriate antihypertensive treatment regimens (6). For example, in patients with diabetes or other additional risk factors, the BP targets are lower: SBP < 130 mmHg and DBP < 80 mmHg, vs. SBP < 140 mmHg and DBP < 90 mmHg in patients with no additional risk factors (2,6,7).
The ultimate goal of hypertension management is to reduce CV morbidity and mortality by preventing end-organ damage (6–8). Numerous intervention studies have shown that BP control is associated with significant reductions in CV morbidity and mortality. Even modest reductions in SBP or DBP for short periods of time substantially improve CV outcomes, particularly in high-risk patients (9). For example, antihypertensive therapy is associated with a 35–40% reduction in stroke, a 20–25% reduction in myocardial infarction, a > 50% reduction in heart failure and reductions in CVD-related death rates (6,10). In addition to appropriate management of additional risk factors and associated clinical conditions, early, intensive and effective BP control is required in the prevention and management of CVD (6,8).

**Blood pressure control and achievement of guideline goals**

Although effective therapies exist, current BP control is still below the ‘Healthy People 2010’ goal of 50%: only 34% of patients with hypertension have adequately controlled BP, 59% have treated but uncontrolled BP and 30% are unaware of their condition (7). Poorly controlled BP, particularly SBP, is associated with increased CV morbidity and mortality, and end-organ damage (11). Despite the availability of effective antihypertensive treatments, adequate BP control is often not achieved, highlighting the need for greater efforts in the management of hypertension.

Hypertension guidelines have traditionally recommended stepwise regimens to lower BP in patients with hypertension, beginning with lifestyle modification (e.g. weight reduction, increased physical activity, dietary changes, smoking cessation and moderation of alcohol consumption), and adding pharmacological intervention when lifestyle changes are insufficient (2,6,7,12). Immediate initiation of antihypertensive therapy, together with lifestyle changes is recommended in individuals at high or very high risk; whereas, for those at low or moderate risk, the effects of lifestyle changes should be monitored for several weeks before initiation of antihypertensive treatment (6). Guidelines also recommend that antihypertensive therapy should be started gradually to achieve target BP values progressively over several weeks.

Data from outcome studies show that several classes of drugs, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCBs) and thiazide-type diuretics, effectively lower BP and reduce the complications of hypertension (10,13–16). However, the recent ESH/ESC guidelines recommend that the presence of additional conditions, such as diabetes or coronary artery disease (CAD), or possible contraindications should be considered when selecting the initial antihypertensive agent (6).

In clinical practice, hypertension management varies greatly and many factors contribute to inadequate BP control, the most important include: patient non-compliance; acceptance of inadequate BP control by clinicians and reluctance to titrate the dose, switch to another drug or add another drug; and the fact that it is difficult to achieve adequate BP control with monotherapy in most patients, even when the dose is optimised (17). Response rates with any class of antihypertensive administered as monotherapy range from 30% to 60%; however, no monotherapy has been shown to achieve target BP in more than 20–30% of the overall hypertensive population (18,19). By contrast, combining two complementary antihypertensive agents has been shown to improve the response rate to 75–90% (17), and the results of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) showed that about nine of 10 patients required two or more antihypertensive agents to reduce BP to <140/90 mmHg (20). Therefore, most patients, particularly those at high CV risk, will require combination therapy with two or more antihypertensive medications to achieve controlled BP, and recent guidelines recommend that two-drug combination therapy be considered a first-line alternative to monotherapy (2,6,7).

Compared with high-dose monotherapy, combination therapy is associated with fewer adverse effects. Guidelines advocate combination therapy with once daily treatment regimens that provide 24-h efficacy. The advantages of combination therapy include improved adherence to therapy (21) and minimisation of BP variability. In addition, combining two antihypertensive agents with different mechanisms of action may provide greater protection against major CV events and the development of end-organ damage (6). The challenge remains to translate the evidence and recommendations outlined in the current hypertension management guidelines into clinical practice, as combination therapy remains underused, especially in high-risk patients (22).

**Combination therapy – the evidence**

Combination therapy was traditionally reserved as a third- or fourth-line approach in hypertension management (7); however, several major intervention trials in various high-risk patient populations have shown that an average of two to four antihypertens-
sive agents are required to achieve effective BP control to target levels (Figure 1) (23–29). A significant level of support for combination therapy is also provided by monotherapy studies in which additional or background antihypertensive therapy was required to effectively lower BP (Table 1) (13,14,16,24–26,30–35).

Guidelines recommend various two-drug combinations of different classes of antihypertensive agents based on data derived from controlled interventional trials, but advise that three or four drugs may be required depending on the patient’s risk profile. Although older therapies such as diuretics and beta-blockers can effectively lower BP and are included as possible first-line combinations, they are associated with some disadvantages (6). For example, beta-blockers offer no benefit to elderly patients with uncomplicated hypertension. Furthermore, they may be associated with an increased risk of stroke (36) and impaired glucose and lipid metabolism (37). These studies recommend that beta-blockers should not be first choice for the treatment of uncomplicated hypertension. When diuretics are administered at higher doses or in combination with beta-blockers, they are associated with increased risks of new-onset diabetes (37). Evidence to support the use of diuretics as first-line treatment has also been questioned and these concerns are reflected in recent guidelines (6).

By contrast, many studies have shown that newer antihypertensive agents, such as CCBs, ARBs and ACE inhibitors, provide additional benefits by reducing the incidence of CV events in patients with hypertension (14,16,25,30). In addition, cases of new-onset diabetes are less common with newer antihypertensive agents than with older therapies such as diuretics and beta-blockers (37). Whether this is due to the deleterious effect of older agents on glucose metabolism or a positive effect of newer agents remains to be fully determined.

**CCBs in combination therapy – evidence supporting additional treatment benefits**

**Combination studies**

Calcium channel blockers are used extensively in clinical practice and data from several clinical studies show that CCBs effectively and safely lower BP and reduce long-term CV risk in a wide range of patient populations (24,32,35,38,39). It is of note that while most studies have investigated the efficacy and safety of dihydropyridine CCBs, there are some studies supporting the benefits of non-dihydropyridine CCBs (33,40,41). However, for the purpose of this review, data presented on CCBs are for dihydropyridine CCBs.

As CCBs have a different mode of action to commonly used inhibitors of the renin–angiotensin–aldosterone (RAAS) pathway (such as ACE inhibitors and ARBs), combination with these agents should provide synergistic or complementary effects, compared with using two agents that inhibit the same pathway. Indeed, in patients with newly diagnosed stage 1 or 2 hypertension or in patients with inadequate BP control after conventional low-dose monotherapy, low-dose combination therapy with CCBs and ARBs was found to provide better BP control than either high-dose monotherapy (p < 0.05 vs. either monotherapy) (42). Further evidence for the

| Study   | Target BP (mmHg) | Number of antihypertensive agents |
|---------|------------------|-----------------------------------|
| UKPDS   | DBP <85          | 1                                 |
| ABCD    | DBP <75          | 2                                 |
| MDRD    | MAP <92          | 3                                 |
| HOT     | DBP <80          | 4                                 |
| AASK    | MAP <92          | 4                                 |
| IDNT    | SBP/DBP 135/85   | 4                                 |
| VALUE   | SBP/DBP 140/90   | 4                                 |

*Figure 1* Two to four antihypertensive agents are required to achieve effective BP control to target levels. UKPDS, United Kingdom Prospective Diabetes Study (23); ABCD, Appropriate Blood Pressure Control in Diabetes (27); MDRD, Modification of Diet in Renal Disease study (28); HOT, Hypertension Optimal Treatment study (24); AASK, African American Study of Kidney Disease and Hypertension (29); IDNT, Irbesartan Diabetic Nephropathy Trial (26); VALUE,Valsartan Antihypertensive Long-term use Evaluation Trial (25); BP, blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; SBP, systolic blood pressure.
The benefits of CCB/ARB combination therapy was provided by Kuschnir et al. (43), who showed that the combination of low-dose nifedipine gastrointestinal therapeutic system (GITS) with losartan was associated with improved BP control (greater and more consistent) than either monotherapy (p < 0.05) in patients with mild-to-moderate hypertension. Similarly, in hypertensive patients in the Nifedipine and Candesartan Combination (NICE-Combi) study, low-dose CCB/ARB combination therapy with nifedipine controlled-release (CR) and candesartan was shown to be more effective than up-titrated candesartan monotherapy for both BP control and renal protection, with significant reductions in urinary microalbumin excretion levels with combination therapy compared with either monotherapy (p < 0.05) (38). The Japanese Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) study was conducted to extend the findings of the NICE-Combi study and determine the optimal CCB (nifedipine CR vs. amlopidine) for combination therapy with valsartan in patients with essential hypertension. BP was significantly reduced in both treatment arms, but to a greater extent in patients receiving nifedipine CR and valsartan than in those receiving amlopidine and valsartan (p < 0.01) (44).

In the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies study, CCB and ACE inhibitor combination therapy with amlodipine and benazepril was significantly more effective in reducing SBP and pulse pressure in patients with severe systolic hypertension than either monotherapy (p < 0.0001) (45). Significantly greater percentages of patients in the combination group achieved reductions in BP to guideline-recommended targets compared with either monotherapy (p < 0.0001) (17). These findings are supported by those of a similar study that investigated a CCB and ACE inhibitor combination therapy with amlopidine and benazepril was significantly more effective in reducing SBP and pulse pressure in patients with severe systolic hypertension than either monotherapy (p < 0.01) (44).

In the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies study, CCB and ACE inhibitor combination therapy with amlopidine and benazepril was significantly more effective in reducing SBP and pulse pressure in patients with severe systolic hypertension than either monotherapy (p < 0.0001) (45). Significantly greater percentages of patients in the combination group achieved reductions in BP to guideline-recommended targets compared with either monotherapy (p < 0.0001) (17). These findings are supported by those of a similar study that investigated a CCB and ACE inhibitor combination therapy with amlopidine and benazepril was significantly more effective in reducing SBP and pulse pressure in patients with severe systolic hypertension than either monotherapy (p < 0.01) (44).
Add-on studies
Data from outcome trials show that CCB therapy plus additional add-on treatment not only lowers BP but also improves patient outcomes. The Hypertension Optimal Treatment trial showed that intensive lowering of BP with CCB-based therapy (felodipine as baseline therapy with the addition of other antihypertensive agents according to a five-step regimen) was associated with a low rate of CV events (22). In the Systolic Hypertension in Europe (Syst-Eur) and China (Syst-China) studies, the dihydropyridine CCB nitrendipine, with the addition of a diuretic and an ACE inhibitor (enalapril in Syst-Eur and captopril in Syst-China) reduced the rate of CV complications in elderly patients with isolated systolic hypertension (35,39). The additional benefits of CCB-based therapy in the elderly patients were further supported by the Shanghai Trial Of Nifedipine in the Elderly, in which nifedipine GITS reduced the incidence of CV events, including stroke, in elderly individuals with hypertension (47).

Data from ASCOT showed that CCB-based treatment is more effective than a beta-blocker-based regimen for reducing mortality and CV events (20). ASCOT compared the combination of the CCB amlodipine plus the ACE inhibitor perindopril (added as required) with the beta-blocker atenolol plus the diuretic bendroflumethiazide (added as required) in a group of patients with hypertension and at least three other CV risk factors (20). Treatment with a CCB-based therapy reduced the risks of non-fatal myocardial infarction or fatal CHD (p = 0.046), fatal and non-fatal stroke (p = 0.0003), total CV events and procedures (p < 0.0001), all-cause mortality (p = 0.025) and diabetes (p < 0.0001) compared with the beta-blocker-based therapy (20). Thus, the CCB-based regimen prevented more major CV events and was associated with a reduced incidence of diabetes compared with the diuretic-based regimen. The results of ASCOT therefore support the benefits of combined antihypertensive therapy for lowering BP and significantly reducing the risk of CV events.

Additional studies
In addition, there are several ongoing studies to determine the optimal antihypertensive combination therapy with the most favourable safety profile for lowering BP and protecting against CV events. The Combination Therapy of Hypertension to Prevent Cardiovascular Events study is a multicentre trial assessing CV outcomes in hypertensive patients treated with various drug combinations including ARBs, beta-blockers or diuretics in combination with a CCB (benidipine) (48). The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension trial is the first randomised controlled trial to compare the effects of ACE inhibitor/diuretic and ACE inhibitor/CCB first-line combination therapies (benazepril/hydrochlorothiazide vs. benazepril/amlo) in hypertensive patients with additional CV risk factors, including renal disease and diabetes (49). Results from these trials should provide new evidence regarding the optimal antihypertensive combination therapy.
evidence to select optimal combination therapies for hypertensive patients.

Several other large, randomised clinical studies have investigated the use of antihypertensive combination therapies in high-risk patient populations, including those with impaired renal function, diabetes or CAD, in whom BP is more difficult to control to target levels. These will be discussed in more detail in the following sections.

**Patients at risk of stroke**

There is strong evidence to show that hypertension is probably the most important risk factor for stroke (50) – the risk of stroke increases linearly with increasing BP (51). In patients at risk of stroke, reducing BP has a significant benefit: a 5–6 mmHg reduction in BP has been shown to reduce the risk of stroke by 38% (52). The CCB-based antihypertensive strategies in particular have been shown to provide specific benefits in patients at risk of stroke (47). The combination of a CCB and an ACE inhibitor has been shown to significantly reduce the risk of stroke in elderly patients with isolated systolic hypertension, with relative risk reductions vs. placebo of 38% (p = 0.01) and 42% (p = 0.003) in Syst-Eur and Syst-China respectively (35,39). More recently, ASCOT demonstrated a greater reduction in the risk of non-fatal or fatal stroke with CCB plus additional ACE inhibitor therapy compared with a beta-blocker plus additional diuretic therapy (p = 0.0003) (20). In A Coronary Disease Treatment Investigating Outcome with Nifedipine GITS (ACTION), the addition of the CCB nifedipine GITS to best practice therapy for CAD, including other antihypertensive agents, reduced the risk of debilitating stroke by 33% in hypertensive patients (p = 0.029) compared with hypertensive patients who did not receive additional CCB therapy (49).

**Benefits of CCB-based therapy in high-risk patient populations**

The safety and efficacy of CCBs have also been demonstrated in several high-risk patient populations, such as those with impaired renal function, diabetes or CAD.

**CCB combination therapy and renal function**

In hypertensive patients at high CV risk, renal dysfunction has been shown to be an important predictor of CV risk and to act as a prognostic marker of progression to CVD (53). Furthermore, BP is more difficult to control in patients with impaired renal function, particularly in those with comorbid diabetes. Importantly, tight BP control has been shown to slow the progression of renal failure (54).

ACTION examined the benefits of additional nifedipine GITS intervention in patients with stable angina and CAD who were receiving best practice therapy. Almost 40% of the patients in ACTION had evidence of renal dysfunction (34,55), and the results showed that, when administered in addition to best practice therapy for CAD, nifedipine GITS significantly reduced BP (p < 0.0001 compared with placebo) even in patients with renal dysfunction in whom it is more difficult to achieve BP control.

In the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), patients with mild-to-moderate hypertension received nifedipine GITS or the diuretic combination co-amilozide, with the addition of atenolol (or enalapril if atenolol was contraindicated) followed by addition of any other antihypertensive drug (other than CCBs or diuretics) if BP targets were not achieved. The study showed that, in hypertensive patients at high CV risk, renal function was better preserved with nifedipine GITS than with diuretics (p < 0.0001). The improved renal function with nifedipine GITS was indicated by better preserved creatinine clearance, which is a marker of renal function, and fewer patients treated with nifedipine GITS had progressive renal deterioration compared with those treated with co-amilozide (34,53).

Further evidence of the benefits of CCBs in patients with impaired renal function was provided by the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial, which included a post hoc analysis of the changes in estimated glomerular filtration rate with a CCB (amlodipine), a diuretic (chlorothalidone) and an ACE inhibitor (lisinopril). In this trial, the incidence of end-stage renal disease was similar for all three treatment arms, but estimated creatinine clearance was significantly better preserved with amlodipine than with chlorothalidone or lisinopril (13). Taken together, the results of these studies demonstrate that dihydropyridine CCBs confer prognostic benefits in terms of renal function.

**CCB combination therapy and diabetes**

Individuals with hypertension have a ≥ 2-fold increased risk of developing diabetes (56). In addition, hypertension is twice as common in patients with diabetes compared with those without diabetes; it accounts for up to 75% of CV risk in this patient population, leading to substantial increases in morbidity and mortality (57).

Hypertension acts synergistically with diabetes in increasing the risks of macro- and microvascular diabetic complications (58,59). In patients with type 1 diabetes mellitus, hypertension is often the result of
underlying nephropathy; whereas in those with type 2 diabetes mellitus, hypertension may be present as part of the metabolic syndrome (60).

Owing to the increased CV risk associated with diabetes, target BP is lower in patients with diabetes (130/80 mmHg) than in patients with primary hypertension (5,6). However, fewer than one-third of individuals with diabetes achieve BP targets, in part because of the inherent difficulty of controlling BP in these patients (59). Current guidelines recognise the importance of achieving target BP levels and recommend that all patients with diabetes and hypertension should be treated with a combination of several antihypertensive drugs (one of which should be an ARB or ACE inhibitor) (6,61).

Several studies have shown that CCB-based combination therapy can improve clinical outcomes in individuals with diabetes. In INSIGHT, nifedipine GITS reduced the risk of all-cause mortality in patients with diabetes compared with those without diabetes and reduced the frequency of new cases of diabetes compared with diuretic therapy (62). Further support for CCB-based combination therapy in patients with diabetes is provided by ACTION, the results of which showed that nifedipine GITS, in addition to best practice therapy for CAD, significantly reduced BP and the risk of CV events (34). The Reduction of Endpoint in NIDDM with the Angiotensin II Receptor Antagonist Losartan study investigated the addition of losartan to current hypertensive medication in patients with diabetes and diabetic nephropathy. Most patients were taking dihydropyridine CCBs, and the addition of losartan led to significant renal-protective effects, with a risk reduction of 28% in end-stage renal disease (p = 0.002). This benefit was beyond that attributable to the BP-lowering effect alone (30,51).

**CCB combination therapy and CAD**

In ACTION, more than 50% of patients had inadequately controlled BP at baseline, despite receiving best practice therapy at study entry (34). At baseline, 20% of patients were receiving ACE inhibitors; ≥10% were receiving diuretics; 2% were receiving ARBs and ≥80% were receiving beta-blockers. The addition of nifedipine GITS to best practice CAD therapy provided further benefit by increasing the proportion of patients who achieved BP targets: the percentage of patients with BP above target was reduced from 52% at baseline to 35% in the nifedi- pine GITS group and 47% in the placebo group. The effects of nifedipine GITS on BP lowering resulted in improved patient outcomes, which were mainly attributable to reductions in stroke or transient ischaemic attack and the need for coronary angiogra-

phy or coronary interventions (34). The benefits of nifedipine GITS intervention were also evident in those patients with additional complications, including patients with underlying atrial fibrillation (63).

Further analysis of the ACTION results revealed even greater benefits in the subgroup of patients with inadequate BP control at baseline (64). There was a significant 13% reduction (p < 0.05) in the combined incidence of all-cause mortality, myocardial infarction, refractory angina, heart failure, debilitating stroke and peripheral revascularisation in patients receiving nifedipine GITS in addition to best practice therapy. In addition, a 38% reduction in new overt heart failure and a 33% reduction in the incidence of debilitating stroke were observed in patients treated with nifedipine GITS. Together, these data clearly indicate that long-acting CCBs are an effective and well-tolerated combination therapy choice in high-risk patients with CAD.

**Benefits of antihypertensive drug combinations with complementary modes of action**

Hypertension is a multifactorial disease, so disruption of a single physiological pathway is often insufficient to control BP. Therefore, a combination of two drugs with different but complementary modes of action is often needed to achieve effective BP control. This is supported by hypertension guidelines, which highlight the need for drugs to be combined effectively and emphasise the benefits of drugs with different mechanisms of action on a multi-regulated variable such as BP (2,6,7).

Dihydropyridine CCBs and inhibitors of the RAAS pathway (namely, ACE inhibitors and ARBs) are widely used in patients with CVD. They have complementary mechanisms of action so, when used in combination, have synergistic effects on pathological changes in the vasculature and end organs, providing benefits in addition to BP control.

Calcium channel blockers primarily affect the cellular interactions of endothelial cells, smooth muscle cells, monocytes and thrombocytes, which have key roles in the early phases of atherosclerosis development. There is also evidence to show that CCBs affect the nitric oxide system in endothelial cells. Several studies have shown that endothelium-dependent relaxation, which is impaired in individuals with hypertension, can be restored by treatment with dihydropyridine CCBs (65–67). CCBs also have vascular-protective effects, which are evident during the later stages of atherosclerosis. The International Nifedipine Trial on Anti-atherosclerotic Therapy study demonstrated a 28% reduction in new
atherosclerotic lesions in patients with mild CAD with nifedipine GITS (68). In patients with significant atherosclerosis, even greater reductions in lesions are observed with a CCB and statin combination, as shown in the Regression Growth Evaluation Statin Study (69). CCBs have also been shown to have beneficial effects on early carotid wall changes by reducing intima-media thickness (70–72), and can improve coronary endothelial function in patients with CAD (73). By contrast, ARBs and ACE inhibitors act on the RAAS hormone pathway to block signalling and promote relaxation of blood vessels, thereby controlling BP and providing beneficial effects on CV morbidity and mortality in high-risk patients and preserving renal function. In addition, it was recently shown that ARBs have a specific anti-inflammatory effect by reducing levels of inflammatory markers such as tumour necrosis factor-α, interleukin-6 and C-reactive protein (74). In addition to effective BP lowering, combination therapy with a CCB and an ARB would be expected to provide additional benefits through effects on both oxidative stress and microinflammation.

Conclusions

Both guideline recommendations and clinical trial evidence support the use of combination therapy in managing hypertension, particularly in patients at increased risk of CV events and those for whom BP targets are lower because of the need for intensive management of additional risk factors, such as those with CAD, metabolic syndrome, diabetes or renal dysfunction. In a large proportion of patients, it is difficult to lower BP to target levels using antihypertensive monotherapy, so more intensive intervention, specifically combination antihypertensive therapy, is often required. Clinical studies have proved the efficacy of CCB-based combination strategies in a wide range of high-risk patient groups.

Combination therapy with antihypertensive agents that have different but complementary mechanisms of action not only avoids unnecessary drug interactions and adverse events, but also maximises the benefits of agents that have additional effects beyond BP lowering. For example, there is evidence to show that the combination of CCBs and ARBs provides end-organ protection through synergistic mechanisms. CCBs are effective with all other antihypertensive agents, and this flexibility makes them ideal as part of a first-line combination strategy to achieve target BP and provide additional CV benefits, without compromising safety in patients at increased CV risk.

In clinical practice, there is still much inconsistency with regards to stepwise treatment of patients and the decision to increase drug dose, switch therapy or add another drug. Combination therapy may still be considered a last resort in the treatment of hypertension and be rarely used as initial or first-line therapy. The treatment paradigm is now changing and more patients are being treated in line with guideline recommendations, which focus on overall CV risk and therefore recommend multiple-drug strategies early in the course of treatment.

Ongoing studies will provide further data to support the benefits of antihypertensive combination therapy on clinical outcomes when used as a first-line strategy. Increased efforts to use combination therapy much earlier in the course of treatment and increased adherence to global guidelines will ensure patients achieve and sustain BP control in addition to reducing the risk of CV events.

Acknowledgements

Educational funding for this manuscript was provided by Bayer Schering Pharma. The author would like to acknowledge Syrah Khan for her support with the development of this manuscript. Syrah Khan is a medical writer at GCL.

References

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23.
2. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–92.
3. World Health Organization. The Atlas of Heart Disease and Stroke. Risk Factor: Blood Pressure. http://www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed September 2007).
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.
5. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89–95.
6. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
7. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.
8. Sica DA. Are current strategies for treating hypertension effective? J Clin Hypertens (Greenwich) 2003; 5: 23–32.
9. McInnes GT. How important is optimal blood pressure control? Clin Ther 2004; 26 Suppl. A: A3–11.
10. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood
Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356: 1955–64.

11 Benetos A, Thomas F, Beau KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21: 1635–40.

12 Chalmers JP, Arnold JF. Lowering blood pressure in 2003. Med J Aust 2003; 179: 306–12.

13 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.

14 Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

15 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.

16 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevenion Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.

17 Neutel JM. The use of combination drug therapy in the treatment of hypertension. Prog Cardiovasc Nurs 2002; 17: 81–8.

18 Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995; 8: 189–92.

19 Morgan TO, Anderson AI, MacInnis RI. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14: 241–7.

20 Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an angiotensin-receptor antagonist of amloide in addition perioprol as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

21 Bangalore S, Kamalakshanan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713–9.

22 Amor J, Veur L, Perret M, Baillie C, Etienne S, Chamontin B. Hypertension in high-risk patients: beware of the underuse of effective treatment (results of the PRATIK study). J Hypertens 2002; 20: 779–84.

23 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.

24 Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62.

25 Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlopidine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.

26 Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.

27 Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 1998; 82: 9R–14R.

28 Lazarus JM, Bourgoignie J, Buckalew VM et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641–50.

29 Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlopidine on renal outcomes in hypertensive nephrosclerosis: a randomised controlled trial. JAMA 2001; 285: 2719–28.

30 Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.

31 Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.

32 Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–23.

33 Pepine CJ, Handberg EM, Cooper-Deloff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA 2003; 290: 2805–16.

34 Poole-Wilson PA, Lubsen J, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–57.

35 Staessen JA, Fagar R, Thisis L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–64.

36 Lindholm LH, Carlberg B, Samuelsson O. Beta blockers in primary hypertension: do age and type of beta-blocker matter? J Hypertens 2006; 24: 2143–5.

37 Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10.

38 Hasebe N, Kikuchi K. NICE-Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005; 23: 445–53.

39 Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823–9.

40 Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.

41 Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.

42 Andreass EA, Tsourous GI, Marakomichelakis GE et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 2005; 19: 491–6.

43 Kuchner F, Bendersky M, Resk J et al. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 2004; 43: 300–5.

44 Saito I, Saruta T. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-comb) study. Hypertens Res 2006; 29: 789–96.

45 Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatinin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) 2005; 7: 641–6.

46 Mugellini A, Vaccarella A, Celentano A, Scanferla F, Zoppi A, Fogari R. Fixed combination of manidipine and delapril in the...
Combination therapy for effective hypertension management

treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press Suppl 2005; 1: 6–13.
47 Gong L, Zhang W, Zhu Y et al. Shanghai Trial Of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14: 1237–45.
48 Ogihara T, Matsuzaki M, MatsuoKA H et al. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: rationale and design. Hypertens Res 2005; 28: 331–8.
49 Jamerson KA, Bakris GL, Wun CC et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17: 793–801.
50 Whisnant JP. Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke 1997; 28: 1840–4.
51 Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499–507.
52 Turnbull F, on behalf of the Blood Pressure Lowering Treatment Trials’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
53 de Leeuw PW, Ruilope LM, Palmer CR et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459–64.
54 Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256–61.
55 Ruilope LM, Kirwan BA, de Brouwer S et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007; 25: 1711–8.
56 Gress TW, Nieto FJ, Shahar E, Wolford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–12.
57 El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep 2004; 6: 215–23.
58 Giusiti S, Cooper M. Management strategies for patients with hypertension and diabetes: why combination therapy is critical. J Clin Hypertens (Greenwich) 2006; 8: 108–13.
59 McFarlane SI, Farag A, Sowers J. Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovasc Drug Rev 2003; 21: 105–18.
60 American Diabetes Association. Standards of medical care in diabetes – 2006. Diabetes Care 2006; 29 (Suppl 1): 54–42.
61 Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.
62 Mancia G, Brown M, Castaigne A et al. Outcomes with nifedipine GITS or co-amiloigide in hypertensive diabetics and non-diabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 2003; 41: 431–6.
63 Otterstad JE, Kirwan BA, Lubsen J et al. Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease. Scand Cardiovasc J 2006; 40: 152–9.
64 Lubsen J, Wagener G, Kirwan BA, Brouwer S, Poole-Wilson PA. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 641–8.
65 Sudano I, Virdis A, Taddei S et al. Chronic treatment with long-acting nifedipine reduces vasoconstruction to endothelin-1 in essential hypertension. Hypertension 2007; 49: 285–90.
66 Taddei S, Virdis A, Ghidioni L et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37: 943–8.
67 Taddei S, Virdis A, Ghidioni L et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001; 19: 1379–86.
68 Lichtlen PR, Hugenholz PG, Raffenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335: 1109–13.
69 Jukema JW, Bruschke AV, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–40.
70 Pitt B, Byington RP, Furberg CD et al. Effect of amldopine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
71 Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amiloigide on the progression of early carotid wall changes. Circulation 2001; 103: 2949–54.
72 Zanchetti A, Bond MG, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422–7.
73 ENCORE I. Effect of nifedipine and amlodipine on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Amlodipine On Recovery of coronary Endothelial function). Circulation 2003; 107: 422–8.
74 Fiser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103–7.

Paper received August 2007, accepted December 2007